SMS Pharmaceuticals Files SEBI Compliance Certificate for Q3 FY26
SMS Pharmaceuticals Limited filed a compliance certificate for the quarter ended December 31, 2025, as per SEBI regulations. The company's RTA confirmed timely dematerialization of securities and updated ownership records.
This is a standard compliance filing related to share dematerialization, which is a routine process for listed companies and typically has no immediate impact on the company's operations or stock price.
The announcement is a routine regulatory filing and does not contain any financial performance indicators or significant business updates that would impact the company's valuation.
SMS Pharmaceuticals Limited has submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2025. The certificate was received from M/s. Aarthi Consultants Private Limited, the company's Registrar and Share Transfer Agent.
This filing confirms compliance with the regulations, indicating that the dematerialization of securities received from depository participants has been processed within 15 days. The actions taken include the mutilation and cancellation of original certificates, and the substitution of the depository's name as the registered owner in the company's records. These securities are listed on the relevant stock exchanges.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.